CSL Seqirus

CSL Seqirus is providing scientific and technical expertise and its well-established MF59 adjuvant technology to the University of Queensland in Australia to help fast-track the development of their CEPI-funded n-COV19 vaccine candidate using novel molecular-clamp technology.

More information